Vectura Group PLC (LSE:VEC) - Share price

Stock Report

Vectura Group PLC VEC

Last Price

Day Change

As of -
- | GBX
Minimum 15 Minutes Delay.

Last Close-p
Day Range-
Mkt Cap1.01Bil
52-Wk Range-
Yield %-

Share Price

Total Returns 18/10/2021

 Chg (%)  
More ...
Vectura Group PLC0.00 
FTSE 100 TR GBP-3.43
More ...
Income Statement
Operating Profit-96.60-23.507.90
Net Profit-88.20-22.10122.40
Reported EPS-13.20-3.4020.10
Balance Sheet
Current Assets170.20146.10305.60
Non Current Assets451.20384.60360.40
Total Assets621.40530.70666.00
Current Liabilities72.3064.1085.20
Total Liabilities127.10111.30121.60
Total Equity494.30419.40544.40
Cash Flow
Operating Cash Flow35.1019.3031.50
Net Change in Cash3.20-32.201.60

Regulatory News

DateAuthor Headline
21/01/2020James Gard How to Profit from Disruption
The internet has turned the consumer world upside down - we look at the leaders and laggards from areas like travel, payments, and cybersecurity
09/10/2019James Gard Can Commodities Companies be ESG Investments?
New ways of measuring emissions are helping to focus minds at energy and commodity firms, but it's harder to convince investors of their ESG attributes 
07/08/2019James Gard Can Income Investors Trust UK Banks?
Payouts and profits are up but PPI, leadership succession problems and Brexit mean the sector remains a risky bet for investors
Director Dealings
More ...
29/09/2021Exercise of OptionMr. William Downie0.00112,2880.00
29/09/2021Sale of OptionMr. William Downie165.001,311,3952,163,802.00
29/09/2021Exercise of OptionMr. William Downie0.001,311,3950.00
29/09/2021Sale of OptionMr. William Downie165.00112,288185,275.00

Company Profile

Vectura Group PLC is engaged in inhaled product formulation, device design and development business offering an integrated inhaled drug delivery platform. The company has developed inhalation products to help patients suffering from airways diseases. It has approx ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. The company's partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork. The company operates in the United Kingdom, Japan, Switzerland, the United States of America, and Rest of the world with maximum revenue from the United Kingdom.


Medical Devices


FTSE All Share

Next Event 20/10/2021

Half-Yearly Results
More ...
PER (E)8.19
Div Yld (E)11.54
PEG (E)0.00
Op Mrgn0.04
EPS Grwth0.00
More ...
Record Date11/10/1928/05/21
More ...
Non-Executive Director, ChairmanMr. Bruno Francois Jules Angelici
Non-Executive DirectorDr. Kevin Roger Kenneth Matthews
Executive Director, Chief Executive OfficerMr. William Downie
Non-Executive DirectorDr. Per-Olof Andersson
Non-Executive DirectorMs. Juliet Thompson
Executive Director, Chief Financial OfficerMr. Paul Andrew Fry
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.